CANPOS: Predictive Biomarkers of Tumor Progression in Non-small Cell Lung Cancer

NCT02764606 | Unknown

• 1 other identifier: D50832
• Study Type: observational
• Target: 250
• Locations: 1 country
• Sites: 1

Brief Summary

CANPOS is a non-interventional study aiming at evaluate at the time of initial surgery the value of new serum markers to predict the occurrence of metastases in patients with early-stage non-small cell lung cancer. This would represent a rational to develop personalized follow-up and prevention strategies

Conditions

Non-small Cell Lung Cancer

Keywords

Lung Cancer; Biomarkers; Bone; Metastases

Outcome Measures

Primary Outcomes (1)

• The Serum levels of osteoprotegerin

  The serum levels of osteoprotegerin, as assessed by standard ELISA methods, will be measured to to evaluate at the time of initial surgery, the value of new serum markers to predict the occurrence of metastases in patients with early-stage non-small cell lung cancer.

  At the time of initial surgery

Study Arms (1)

Patients with a non-small cell lung cancer

Serum and plasma samples (at time of diagnosis, after surgery, and at time of progression to evaluate the value of new serum markers to predict the occurrence of metastases).

Biological: Serum and plasma samples

Interventions

Serum and plasma samples BIOLOGICAL

Serum and plasma are collected at time of diagnosis, after surgery, and at time of progression to evaluate the value of new serum markers to predict the occurrence of metastases.

Patients with a non-small cell lung cancer

Eligibility Criteria

• Age: 18 Years - 70 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Early-stage non-small cell lung cancer

You may qualify if:

• patients with a diagnosis or suspected for a diagnosis of lung cancer, non-small cell lung cancer
• age over 18 years
• patient naïve of any oncology treatment (excluding surgery alone) within the past 5 years
• patient who signed the informed consent by the study protocol

You may not qualify if:

• any ongoing treatment for cancer
• any history of cancer within 5 years before the diagnosis of lung cancer
• any psychological, sociological or geographical conditions that would not allow the study follow-up

Sponsors & Collaborators

• Hospices Civils de Lyon: lead

Study Sites (1)

Hospices Civils de Lyon / Hôpital Neurologique Pierre Wertheimer

Bron, 69500, France

RECRUITING

Biospecimen

Retention: SAMPLES WITH DNA

Serum and plasma

MeSH Terms

Conditions

Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Neoplasm Metastasis

Condition Hierarchy (Ancestors)

Carcinoma, Bronchogenic; Bronchial Neoplasms; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases; Neoplastic Processes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Central Study Contacts

Nicolas Girard

CONTACT

+33427857700; nicolas.girard@chu-lyon.fr

Cyrille Confavreux

CONTACT

+33472117482; cyrille.confavreux@chu-lyon.fr

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 28, 2016
• First Posted: May 6, 2016
• Study Start: November 1, 2013
• Primary Completion: December 1, 2025
• Study Completion: December 1, 2025
• Last Updated: April 2, 2019

Record last verified: 2019-04

Locations

FR (1)